Taking Gene Therapy into the Clinic

von Palmer, Daniel H., Chen, Ming-Jen, Kerr, David J.
Veröffentlicht 2003

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

von Elmetwali, Taha, Searle, Peter F, McNeish, Iain, Young, Lawrence S, Palmer, Daniel H
Veröffentlicht 2010

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation

von Elmetwali, Taha, Salman, Asmaa, Wei, Wenbin, Hussain, Syed A., Young, Lawrence S., Palmer, Daniel H.
Veröffentlicht in Sci Rep (2020)

Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre

von Faluyi, Olusola O, Connor, Joanna L, Chatterjee, Madhuchanda, Ikin, Carl, Wong, Helen, Palmer, Daniel H
Veröffentlicht in Br J Cancer (2017)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma

von Middleton, Gary, Greenhalf, William, Costello, Eithne, Shaw, Victoria, Cox, Trevor, Ghaneh, Paula, Palmer, Daniel H, Neoptolemos, John P
Veröffentlicht in Br J Cancer (2016)

Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer

von Ma, Yuk Ting, Leonard, Sarah M., Gordon, Naheema, Anderton, Jennifer, James, Claire, Huen, David, Woodman, Ciaran B., Palmer, Daniel H.
Veröffentlicht in Oncotarget (2017)

Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research

von Evans, Jonathan P, Winiarski, Boleslaw K, Sutton, Paul A, Ressel, Lorenzo, Duckworth, Carrie A, Pritchard, D Mark, Palmer, Daniel H, Goldring, Christopher E, Kitteringham, Neil R
Veröffentlicht in Lab Anim (2019)

A Phase Ib Study of NUC‐1031 in Combination with Cisplatin for the First‐Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC‐08)

von McNamara, Mairéad G., Bridgewater, John, Palmer, Daniel H., Faluyi, Olusola, Wasan, Harpreet, Patel, Alkesh, Ryder, William D., Barber, Safia, Gnanaranjan, Chathunissa, Ghazaly, Essam, Evans, T.R. Jeff, Valle, Juan W.
Veröffentlicht in Oncologist (2020)

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

von Quaranta, Valeria, Rainer, Carolyn, Nielsen, Sebastian R., Raymant, Meirion L., Ahmed, Muhammad S., Engle, Dannielle D., Taylor, Arthur, Murray, Trish, Campbell, Fiona, Palmer, Daniel H., Tuveson, David A., Mielgo, Ainhoa, Schmid, Michael C.
Veröffentlicht in Cancer Res (2018)

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

von Palmer, Daniel H., Valle, Juan W., Ting Ma, Yuk, Faluyi, Olusola, Neoptolemos, John P., Jensen Gjertsen, Trine, Iversen, Berit, Amund Eriksen, Jon, Møller, Anne-Sophie, Aksnes, Anne-Kirsti, Miller, Robert, Dueland, Svein
Veröffentlicht in Br J Cancer (2020)

The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The...

von Loughney, Lisa, West, Malcolm A., Kemp, Graham J., Rossiter, Harry B., Burke, Shaunna M., Cox, Trevor, Barben, Christopher P., Mythen, Michael G., Calverley, Peter, Palmer, Daniel H., Grocott, Michael P. W., Jack, Sandy
Veröffentlicht in Trials (2016)

Gene expression profiling in bladder cancer identifies potential therapeutic targets

von Hussain, Syed A., Palmer, Daniel H., Syn, Wing-Kin, Sacco, Joseph J., Greensmith, Richard M.D., Elmetwali, Taha, Aachi, Vijay, Lloyd, Bryony H., Jithesh, Puthen V., Arrand, John, Barton, Darren, Ansari, Jawaher, Sibson, D. Ross, James, Nicholas D.
Veröffentlicht in Int J Oncol (2017)

The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a ra...

von Loughney, Lisa, West, Malcolm A., Moyses, Helen, Bates, Andrew, Kemp, Graham J., Hawkins, Lesley, Varkonyi-Sepp, Judit, Burke, Shaunna, Barben, Christopher P., Calverley, Peter M., Cox, Trevor, Palmer, Daniel H., Mythen, Michael G., Grocott, Michael P. W., Jack, Sandy
Veröffentlicht in Perioper Med (Lond) (2021)

Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position

von Jones, Christopher M., Radhakrishna, Ganesh, Aitken, Katharine, Bridgewater, John, Corrie, Pippa, Eatock, Martin, Goody, Rebecca, Ghaneh, Paula, Good, James, Grose, Derek, Holyoake, Daniel, Hunt, Arabella, Jamieson, Nigel B., Palmer, Daniel H., Soonawalla, Zahir, Valle, Juan W., Hawkins, Maria A., Mukherjee, Somnath
Veröffentlicht in Br J Cancer (2020)

Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”

von Jones, Christopher M., Radhakrishna, Ganesh, Aitken, Katharine, Bridgewater, John, Corrie, Pippa, Eatock, Martin, Goody, Rebecca, Ghaneh, Paula, Good, James, Grose, Derek, Holyoake, Daniel, Hunt, Arabella, Jamieson, Nigel B., Palmer, Daniel H., Soonawalla, Zahir, Valle, Juan W., Hawkins, Maria A., Mukherjee, Somnath
Veröffentlicht in Br J Cancer (2020)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

von Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A
Veröffentlicht in Lancet Oncol (2015)

The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

von Evans, Jonathan P., Winiarski, Boleslaw K., Sutton, Paul A., Jones, Robert P., Ressel, Lorenzo, Duckworth, Carrie A., Pritchard, D. Mark, Lin, Zhi-Xiu, Vicky, Fretwell L., Tweedle, Elizabeth M., Costello, Eithne, Goldring, Christopher E., Copple, Ian M., Park, B. Kevin, Palmer, Daniel H., Kitteringham, Neil R.
Veröffentlicht in Oncotarget (2018)

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

von Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H, Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.
Veröffentlicht in Br J Cancer (2018)

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

von Evans, Jonathan P., Winiarski, Boleslaw K., Sutton, Paul A., Jones, Robert P., Ressel, Lorenzo, Duckworth, Carrie A., Pritchard, D. Mark, Lin, Zhi-Xiu, Fretwell, Vicky L., Tweedle, Elizabeth M., Costello, Eithne, Goldring, Christopher E., Copple, Ian M., Park, B. Kevin, Palmer, Daniel H., Kitteringham, Neil R.
Veröffentlicht in Oncotarget (2019)

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

von Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W
Veröffentlicht in Lancet Oncol (2021)